NanoViricides (NNVC)
(Real Time Quote from BATS)
$1.50 USD
+0.01 (0.67%)
Updated Oct 18, 2024 11:54 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
NNVC 1.50 +0.01(0.67%)
Will NNVC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NNVC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NNVC
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
NanoViricides files annual report on Form 10-K
NanoViricides plans to advance NV-387 into Phase II clinical trials
NanoViricides says made 'significant progress' in NV-387 regulatory advancement